drugset
drugset / Trial / NCT01765790

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

NCT01765790 ↗

Phase 1 Completed 68 enrolled Baxalta now part of Shire
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).

Timeline

Start
2012-06-14
Primary completion
2016-07-28
Completion
2016-07-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject imalumab Protein / enzyme biologic 1 mg/kg Intravenous
Subject imalumab Protein / enzyme biologic 10 mg/kg Intravenous
Subject imalumab Protein / enzyme biologic 25 mg/kg Intravenous
Subject imalumab Protein / enzyme biologic 37.5 mg/kg Intravenous
Subject imalumab Protein / enzyme biologic 50 mg/kg Intravenous

Indications

colorectal adenocarcinoma